Table 1 |
|||
|
IRS expression in human cancer |
|||
|
Cancer Type |
IRS Expression |
Notes |
Ref(s) |
|
|
|||
|
Breast |
↑ IRS-1 |
Well differentiated primary tumors |
|
|
↑ IRS-1 |
Nuclear IRS-1 correlates with good prognosis |
[46] |
|
|
↓ IRS-1 |
Poorly differentiated, high grade tumors |
||
|
|
|||
|
Hepatocellular |
↑ IRS-1 |
mRNA/protein increased in HCC |
|
|
↑ IRS-2 |
mRNA/protein increased in HCC |
||
|
↑ IRS-4 |
mRNA increased in HCC |
[39] |
|
|
|
|||
|
Lung |
↓ IRS-1 |
Larger (stage 1B) tumors, squamous cell carcinoma |
[47] |
|
|
|||
|
Medulloblastoma |
↑ IRS-1 |
Co-localized with polyoma JCV T-antigen in nucleus |
[42] |
|
|
|||
|
Mesothelioma |
↑ IRS-1 |
mRNA increased in malignant pleural mesothelioma |
[37] |
|
↑ IRS-2 |
mRNA increased in malignant pleural mesothelioma |
[37] |
|
|
|
|||
|
Ovarian |
↑ IRS-1 |
Protein increased in malignant epithelial tumors |
[44] |
|
|
|||
|
Pancreatic |
↑ IRS-1 |
mRNA increased in 7/16 tumors |
[34] |
|
↑ IRS-2 |
mRNA/protein increased in ductal-like cancer cells |
[35] |
|
|
|
|||
|
Prostate |
↑ IRS-1 |
Protein increased in tumors and metastases |
[36] |
|
↑ IRS-2 |
Protein correlates with increased Myc expression |
[40] |
|
|
|
|||
|
Renal |
↑ IRS-2 |
mRNA increased in clear cell carcinomas |
[48] |
|
↑ IRS-5 |
mRNA increased in clear cell carcinomas |
[48] |
|
|
|
|||
|
Mardilovich et al. Cell Communication and Signaling 2009 7:14 doi:10.1186/1478-811X-7-14 |
|||
